Clayson, Darren J.; Wild, Diane J.; Quarterman, Paul; … - In: PharmacoEconomics 24 (2006) 8, pp. 751-765
With the advent of highly active antiretroviral therapy (HAART), HIV-infected patients are living longer and are concerned not only with a treatment's ability to extend their life but also with the quality of the life they are able to lead. Regulatory authorities are also paying closer attention...